2197 Stock Overview A biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Clover Biopharmaceuticals, Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Clover Biopharmaceuticals Historical stock prices Current Share Price HK$0.23 52 Week High HK$0.58 52 Week Low HK$0.20 Beta 3.62 1 Month Change -8.40% 3 Month Change -30.61% 1 Year Change -51.28% 3 Year Change -98.07% 5 Year Change n/a Change since IPO -98.24%
Recent News & Updates
Clover Biopharmaceuticals, Ltd. Announces Positive Additional Immunogenicity and Safety Data in Older Adult & Elderly Subjects from Its Phase I Trial Evaluating SCB-1019 Oct 29
New major risk - Share price stability Oct 02
First half 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.53 profit in 1H 2023) Sep 25
New major risk - Financial position Aug 29
Clover Biopharmaceuticals, Ltd. to Report Q2, 2024 Results on Aug 27, 2024 Aug 15
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults Jun 19 See more updates
Clover Biopharmaceuticals, Ltd. Announces Positive Additional Immunogenicity and Safety Data in Older Adult & Elderly Subjects from Its Phase I Trial Evaluating SCB-1019 Oct 29
New major risk - Share price stability Oct 02
First half 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.53 profit in 1H 2023) Sep 25
New major risk - Financial position Aug 29
Clover Biopharmaceuticals, Ltd. to Report Q2, 2024 Results on Aug 27, 2024 Aug 15
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults Jun 19 Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding Apr 12
Clover Biopharmaceuticals, Ltd., Annual General Meeting, Jun 20, 2024 Mar 28
New major risk - Negative shareholders equity Mar 28
Clover Biopharmaceuticals, Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia Dec 31
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate Dec 13
New minor risk - Market cap size Dec 07
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil Nov 08
New minor risk - Market cap size Oct 19
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China Sep 12
Founder recently bought HK$1.2m worth of stock Sep 06
CEO & Executive Director recently bought HK$595k worth of stock Aug 29
New major risk - Financial position Aug 24
Clover Biopharmaceuticals, Ltd. to Report First Half, 2023 Results on Aug 22, 2023 Aug 09
Clover Biopharmaceuticals, Ltd. Provides Updates on Business and R&D Pipeline Development Jul 11 Clover Biopharmaceuticals, Ltd. announced that it has received $48.882447 million in funding May 10
Companies Like Clover Biopharmaceuticals (HKG:2197) Are In A Position To Invest In Growth Mar 17
Clover Launches Covid-19 Booster Vaccine in the People’s Republic of China Feb 15
Clover Biopharmaceuticals, Ltd. Provides Updates on COVID-19 Vaccine Commercial Launch Jan 17
Founder recently bought HK$1.0m worth of stock Dec 21
Clover Biopharmaceuticals, Ltd. Announces COVID-19 Vaccine, SCB-2019 (CpG 1018/ Alum), Has Been Evaluated by Relevant Authorities of the People's Republic of China and Included for Emergency Use in the PRC Dec 07
Clover Biopharmaceuticals, Ltd. Announces Vaccine Candidate Reduced Household Transmission of SARS-COV-2 by 84% in Study Published in Clinical Infectious Diseases Dec 01
Is Clover Biopharmaceuticals (HKG:2197) In A Good Position To Deliver On Growth Plans? Nov 29
Less than half of directors are independent Nov 16
Clover Biopharmaceuticals, Ltd. Announces Board Changes Oct 29
Founder recently bought HK$636k worth of stock Oct 28
Founder recently bought HK$421k worth of stock Oct 21
Founder recently bought HK$1.2m worth of stock Oct 15
Clover Biopharmaceuticals, Ltd.'s COVID-19 Vaccine Candidate Receives European Union GMP Certificate Sep 21
Clover Biopharmaceuticals, Ltd. Announces Positive Data from Its Ongoing Phase 3 Study Evaluating IT’S SCB-2019 Sep 20
Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine Sep 07
Clover Biopharmaceuticals, Ltd. Announces Covid-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine Sep 06
Will Clover Biopharmaceuticals (HKG:2197) Spend Its Cash Wisely? Aug 31
Clover Biopharmaceuticals, Ltd.’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5 Aug 30
Clover Announces Positive Phase 2/3 Results in Adolescents for Its Covid-19 Vaccine Aug 26
Clover Biopharmaceuticals, Ltd. to Report First Half, 2022 Results on Aug 23, 2022 Aug 13 Clover Biopharmaceuticals, Ltd. Announces Executive Changes
Clover Biopharmaceuticals, Ltd. Announces New Positive Clinical Data in Individuals Vaccinated with A Third Dose of Scb-2019 as A Homologous Booster Against the Omicron Variant Jun 28 Clover Biopharmaceuticals, Ltd. Appoints Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to Board of Directors Jun 21
Clover Biopharmaceuticals, Ltd. Doses First Patient with Scb-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia Jun 15
Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines Jun 14
Clover Biopharmaceuticals, Ltd. Doses First Participants in Phase 1 Trial with SCB-2020S, Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate Jun 01
We're Hopeful That Clover Biopharmaceuticals (HKG:2197) Will Use Its Cash Wisely Apr 28
Less than half of directors are independent Apr 27
Clover Biopharmaceuticals, Ltd. Announces Board Changes Apr 23 Clover Biopharmaceuticals, Ltd., Annual General Meeting, May 27, 2022
Clover Biopharmaceuticals, Ltd. (HKG:2197) Shares Could Be 28% Below Their Intrinsic Value Estimate Feb 05
Clover Biopharmaceuticals, Ltd. Appoints Nicholas Jackson as President of Global Research and Development Feb 02
Clover Biopharmaceuticals, Ltd. Announces Publication in the Lancet Showing that SCB-2019 (CPG 1018/ALUM) in Phase 2/3 Clinical Trial Demonstrates Efficacy Against Entire Severity Spectrum of COVID-19 Jan 22
Clover Biopharmaceuticals, Ltd. Dosing of First Participants with Homologous Booster Dose of Covid-19 Vaccine Candidate in Spectra Jan 06
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis Dec 10
Clover Biopharmaceuticals, Ltd. Initiates Investigator-Led, Phase 2 Trial to Evaluate the Immunogenicity and Safety of Heterologous and Homologous COVID-19 Booster Vaccines Nov 27
Less than half of directors are independent Nov 05 Shareholder Returns 2197 HK Biotechs HK Market 7D 2.2% -0.1% 2.1% 1Y -51.3% -0.6% 23.7%
See full shareholder returns
Return vs Market: 2197 underperformed the Hong Kong Market which returned 23.7% over the past year.
Price Volatility Is 2197's price volatile compared to industry and market? 2197 volatility 2197 Average Weekly Movement 5.9% Biotechs Industry Average Movement 8.1% Market Average Movement 6.5% 10% most volatile stocks in HK Market 14.0% 10% least volatile stocks in HK Market 3.0%
Stable Share Price: 2197 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2197's weekly volatility has decreased from 12% to 6% over the past year.
About the Company Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.
Show more Clover Biopharmaceuticals, Ltd. Fundamentals Summary How do Clover Biopharmaceuticals's earnings and revenue compare to its market cap? 2197 fundamental statistics Market cap HK$297.03m Earnings (TTM ) -HK$939.84m Revenue (TTM ) HK$30.71m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2197 income statement (TTM ) Revenue CN¥28.90m Cost of Revenue CN¥475.67m Gross Profit -CN¥446.77m Other Expenses CN¥437.51m Earnings -CN¥884.29m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.68 Gross Margin -1,546.04% Net Profit Margin -3,060.02% Debt/Equity Ratio -25.6%
How did 2197 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/19 02:38 End of Day Share Price 2025/01/17 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clover Biopharmaceuticals, Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Credit Suisse Yang Huang Credit Suisse Ziyi Chen Goldman Sachs
Show 0 more analysts 
